1. Home
  2. EOT vs CHRS Comparison

EOT vs CHRS Comparison

Compare EOT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Municipal Income Trust EATON VANCE NATIONAL MUNICIPAL OPPORTUNITIES TRUST

EOT

Eaton Vance Municipal Income Trust EATON VANCE NATIONAL MUNICIPAL OPPORTUNITIES TRUST

HOLD

Current Price

$17.05

Market Cap

264.2M

Sector

Finance

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.90

Market Cap

291.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOT
CHRS
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.2M
291.5M
IPO Year
2009
2014

Fundamental Metrics

Financial Performance
Metric
EOT
CHRS
Price
$17.05
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
32.4K
1.0M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
1.43
Revenue
N/A
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
$1.31
Revenue Growth
N/A
N/A
52 Week Low
$15.77
$0.72
52 Week High
$18.00
$2.62

Technical Indicators

Market Signals
Indicator
EOT
CHRS
Relative Strength Index (RSI) 46.39 62.46
Support Level $16.53 $1.55
Resistance Level $17.17 $2.00
Average True Range (ATR) 0.30 0.10
MACD 0.02 0.03
Stochastic Oscillator 74.33 82.89

Price Performance

Historical Comparison
EOT
CHRS

About EOT Eaton Vance Municipal Income Trust EATON VANCE NATIONAL MUNICIPAL OPPORTUNITIES TRUST

Eaton Vance National Municipal Opportunities Trust is a diversified, closed-end management investment company. The company's investment objective is to provide current income exempt from regular federal income tax and to achieve capital appreciation. The company invests a majority of its assets in debt obligations issued by or on behalf of states, territories, and possessions of the United States, including the District of Columbia, and their political subdivisions, agencies, or instrumentalities, the interest on which is exempt from regular federal income tax.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: